Ellex Medical Lasers logo

ELX - Ellex Medical Lasers Share Price

A$0.59 0.0  0.9%

Last Trade - 5:10am

Sector
Healthcare
Size
Micro Cap
Market Cap £45.5m
Enterprise Value £45.4m
Revenue £43.9m
Position in Universe 725th / 1837
Bullish
Bearish
Unlock ELX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ELX Revenue Unlock ELX Revenue

Net Income

ELX Net Income Unlock ELX Revenue

Normalised EPS

ELX Normalised EPS Unlock ELX Revenue

PE Ratio Range

ELX PE Ratio Range Unlock ELX Revenue

Dividend Yield Range

ELX Dividend Yield Range Unlock ELX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ELX EPS Forecasts Unlock ELX Revenue
Profile Summary

Ellex Medical Lasers Limited designs and manufactures lasers and ultrasound systems. The Company is also engaged in the distribution and service of medical devices to ophthalmologists to diagnose and treat eye disease, and manufacture and distribution of lasers and ultrasound. Its segments include Distributors, which sells ophthalmic medical equipment to independent third-party distributors across the globe and Direct, which sells ophthalmic medical equipment to the end user customer in various markets around the world. Its products include ultra Q, Solo, Tango, iTrack, ultra Q reflex, solitaire, integer pro scan, integer pro and 2RT. Selective Laser Trabeculoplasty with Tango and Solo addresses early-stage glaucoma. Its iTrack addresses late-stage glaucoma. Its ultra Q and ultra Q reflex addresses cataracts and vitreous floaters. Its integer pro and integer pro scan addresses diabetic disease of retina. Its 2RT addresses early-stage age-related macular degeneration and macula edema.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated May 11, 1970
Public Since October 12, 1987
No. of Shareholders: 4,099
No. of Employees: 130
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 143,601,138
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ELX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ELX
Upcoming Events for ELX
Similar to ELX
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.